 A*STAR further announced that its second locally developed cancer drug, ETC-206, which targets blood cancers, has advanced to first-in-man trials in 2016.A*STAR would also be building a centre for large molecules, known as the Experimental Biologics Centre (EBC).In 2016, A*STAR's commercialisation arm, A*ccelerate (formerly ETPL) opened the first-of-its-kind “open innovation lab” and the incubator known as A*START Central with 10 medtech, biotech and Internet start-ups on board.